Fosinopril Side Effects
Some side effects of fosinopril may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to fosinopril: oral tablet
Along with its needed effects, fosinopril may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking fosinopril:Less common
- Blurred vision
- chest pain or discomfort
- cold sweats
- dizziness, faintness, or lightheadedness when getting up from a lying or sitting position suddenly
- fast, slow, or irregular heartbeat
- pounding or rapid pulse
- unusual tiredness or weakness
Some side effects of fosinopril may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Body aches or pain
- difficult breathing
- ear congestion
- loss of voice
- muscle or bone pain
- nasal congestion
- nausea and vomiting
- runny nose
- sore throat
For Healthcare Professionals
Applies to fosinopril: oral tablet
General side effects including headache (3.2%) have been reported. Other general side effects including fatigue, weakness, weight gain, sensation of cold, fall, pain and excessive sweating have been reported.
Nervous system side effects have included dizziness (2% to 12%) and headache (up to 3%). Rare nervous system side effects have included lightheadedness, paresthesia, lightheadedness, fatigue, transient ischemic attacks, cerebral infarction, tinnitus, dysgeusia, and sleep disturbance.
Gastrointestinal side effects have occurred in approximately 1% to 2% of patients and have included nausea, general abdominal pain, diarrhea, dysgeusia, and dry mouth. Rare gastrointestinal problems that have been rarely associated with the use of fosinopril have included pancreatitis, dysphagia, abdominal distention, flatulence, constipation, heartburn, and appetite/weight changes.
Cardiovascular side effects have most commonly included mild first dose hypotension (2.4%) and orthostatic hypotension (1.4%). Shock (0.2%) has rarely been associated with the use of this drug. Rare cardiovascular problems associated with the use of fosinopril, but without clear causal effect, have included angina, myocardial infarction, cerebrovascular accident, hypertensive crisis, rhythm disturbances, palpitations, flushing, sudden death, cardiorespiratory arrest, conduction disorders, syncope, and claudication.
Metabolic effects have included hyperkalemia in 2% of patients and rare reports of gout.
Risk factors for the development of hyperkalemia include preexisting renal disease, diabetes mellitus, and the concomitant use of potassium-sparing diuretics.
Data show that total serum cholesterol and lipoprotein A levels are significantly decreased during fosinopril therapy relative to placebo.
Respiratory side effects have included an idiosyncratic cough in approximately 2% to 10% of patients. Rare cases of asthma, bronchospasm, tracheobronchitis, abnormal breathing, pleuritic chest pain, abnormal vocalization, pharyngitis, sinusitis/rhinitis and laryngitis/hoarseness have been reported.
A rare syndrome of cough, bronchospasm, and eosinophilia is reported in two patients treated with fosinopril.
A retrospective study has revealed a significantly higher incidence of discontinuation of angiotensin converting enzyme inhibitor therapy due to cough among black patients compared to non-black patients (9.6% vs. 2.4%).
Several agents have been studied for treating cough with ACE inhibitors. No long term trials exist to allow a definitive treatment option. Cromolyn has the most data showing some benefit. Other agents studied include baclofen, theophylline, sulindac, and benzonatate.
Patients with intestinal angioedema generally present with abdominal pain (with or without nausea or vomiting) and in some cases there was no prior history of facial angioedema, and C-1 esterase levels were normal. These symptoms resolve after stopping the ACE inhibitor.
Hypersensitivity reactions to angiotensin converting enzyme (ACE) inhibitors may be life threatening. Angioedema of the face, extremities, lips, tongue, glottis and/or pharynx have been reported rarely in patients receiving ACE inhibitors. In addition, intestinal angioedema has been reported in patients treated with ACE inhibitors. It is recommended that any patient with dyspnea, dysphagia, or significant facial angioedema stop therapy immediately and avoid ACE inhibitor therapy in general.
Renal impairment is very rare. Essentially no changes in serum creatinine have been reported except for rare cases associated with fosinopril-induced hypotension. Fosinopril-induced renal insufficiency is more likely in patients with a history of congestive heart failure, preexisting renal insufficiency, renal artery stenosis, sodium or intravascular volume depletion or who are on concurrent antihypertensives.
Experts recommend discontinuation of therapy with this drug if jaundice or markedly elevated hepatic serum enzymes develop.
Hepatic side effects associated with the use of fosinopril or other ACE inhibitors have included a rare syndrome that begins with cholestatic jaundice and progresses to fulminant hepatic necrosis and sometimes death. Rare hepatic side effects have included hepatomegaly and hepatitis.
Genitourinary complaints have included impotence in 1% of male patients. More rare genitourinary complaints have included abnormal urination, kidney pain, renal insufficiency and urinary frequency.
Hematologic side effects including lymphadenopathy, decreases in hematocrit, and increases in the blood urea nitrogen, serum creatinine and serum potassium have been reported. Agranulocytosis and neutropenia, which have occurred with other ACE inhibitors, have not been associated with fosinopril. Rare reports of decreased white blood cell counts have been reported.
An 83-year-old lady taking fosinopril 20 mg/day was diagnosed with scleroderma six months after beginning fosinopril therapy and a 59-year-old female taking 20 mg/day was diagnosed with eosinophilic fasciitis five months after beginning therapy. Although it can not be proved, the physician felt that the appearance of these illnesses pointed to fosinopril therapy in each case due to (1) both scleroderma and eosinophilic fasciitis are rare disorders, (2) in both cases, the symptoms appeared a few months after therapy initiation with fosinopril, (3) the second patient with eosinophilic fasciitis presented with a cough one month after beginning fosinopril therapy, (4) the onset in both cases was sudden and progressed rapidly; the clinical course stabilized once the fosinopril was discontinued.
Immunologic side effects including one case of scleroderma and eosinophilic fasciitis has been reported.
Psychiatric symptoms have included memory disturbances, tremor, confusion, behavior and mood changes, and depression.
Musculoskeletal side effects have included musculoskeletal pain in approximately 3% of patients. Rarely, arthralgias, myalgias/muscle cramp, swelling of an extremities and weakness of an extremity have been reported.
Ocular side effects have included vision disturbance and eye irritation.
Dermatological side effects have included urticaria, rash, photosensitivity, and pruritus.
More about fosinopril
- Other brands: Monopril
Compare with other treatments for:
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.